Late-life delivery of FGF21 gene therapy via muscle targeting extended median lifespan in mice by 20.5% while improving metabolic health, mitochondrial function, and reducing age-related pathology across multiple organs. The intervention mimics metabolic benefits of exercise and caloric restriction without requiring sustained behavioral change.
Key Points
- FGF21 gene therapy increased lifespan 20.5% when administered at 13 months
- Treated mice lost weight without reducing food intake via increased energy expenditure
- Prevented organ pathology: amyloidosis, fibrosis, inflammation in liver, kidney, heart
Longevity Analysis
This work demonstrates that metabolic dysregulation—the progressive decline in how cells generate and utilize energy—can be targeted pharmaceutically even after significant aging has begun. By restoring mitochondrial capacity and energy coordination in aged animals, the intervention prevented cascading organ dysfunction that typically accelerates in late life. The durability of the effect through a single gene delivery addresses a practical barrier to sustained interventions: behavioral compliance. Rather than requiring decades of exercise adherence or caloric restriction, the therapeutic approach embeds the beneficial signal within muscle tissue, creating a persistent metabolic environment that resists age-related decline.
Original published by LifeSpan.io, by Arkadi Mazin.